Jane Street Group, LLC Stoke Therapeutics, Inc. Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

A detailed history of Jane Street Group, LLC transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 330,442 shares of STOK stock, worth $3.98 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

330,442

Previous 75,414 338.17%

Holding current value

$3.98 Million

Previous $1.02 Million 298.92%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$12.24 - $15.92 $3.12 Million - $4.06 Million	255,028 Added 338.17%	330,442 $4.06 Million
Q2 2024 Aug 14, 2024	BUY	$11.03 - $17.52 $673,271 - $1.07 Million	61,040 Added 424.66%	75,414 $1.02 Million
Q1 2024 May 15, 2024	SELL	$4.12 - $14.17 $150,017 - $515,958	-36,412 Reduced 71.7%	14,374 $194,000
Q4 2023 Feb 14, 2024	BUY	$3.37 - $5.4 $171,148 - $274,244	50,786 New	50,786 $267,000
Q1 2023 May 15, 2023	BUY	$7.65 - $10.38 $98,348 - $133,445	12,856 Added 62.31%	33,487 $278,000
Q4 2022 Feb 14, 2023	BUY	$7.07 - $15.69 $23,359 - $51,839	3,304 Added 19.07%	20,631 $190,000
Q3 2022 Nov 14, 2022	BUY	$12.56 - $22.53 $217,627 - $390,377	17,327 New	17,327 $222,000
Q2 2021 Aug 16, 2021	SELL	$30.53 - $41.09 $327,220 - $440,402	-10,718 Closed	0 $0
Q1 2021 May 18, 2021	BUY	$36.08 - $69.81 $218,392 - $422,559	6,053 Added 129.75%	10,718 $416,000
Q4 2020 Feb 17, 2021	SELL	$33.62 - $61.93 $53,388 - $98,344	-1,588 Reduced 25.4%	4,665 $289,000
Q3 2020 Nov 17, 2020	SELL	$22.23 - $37.48 $90,009 - $151,756	-4,049 Reduced 39.3%	6,253 $209,000
Q2 2020 Aug 17, 2020	BUY	$20.26 - $29.73 $208,718 - $306,278	10,302 New	10,302 $245,000

Others Institutions Holding STOK

# of Institutions

123

Shares Held

57.6M

Call Options Held

9.3K

Put Options Held

35.2K

View Full List

About Stoke Therapeutics, Inc.

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $474M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

More about STOK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Stoke Therapeutics, Inc. Transaction History